Latest Diagnostics News

Memphasys has secured $1.2 million through a share placement to support the global expansion and manufacturing scale-up of its Felix™ sperm selection system. The company also extended a major convertible note, reinforcing financial flexibility amid growing international contracts.

INOVIQ Limited confirms no undisclosed price-sensitive information amid recent share price surge, attributing the move to external research spotlighting upcoming EXO-OC ovarian cancer test data.

Savannah Goldfields reports metallurgical test results showing over 70% gold recovery from sulphide ores at Electric Light and Red Dam, processed through the existing Georgetown plant. Historic data suggests flotation could boost recoveries above 94%, with further test work planned.

Charter Hall Social Infrastructure REIT (CQE) has acquired a 25% interest in a $53 million Brisbane pathology lab leased to Sonic Healthcare under a 20-year triple-net lease, while divesting early learning assets and reaffirming FY26 guidance.

Elixir Energy has successfully completed a key pressure test on its Lorelle-3H well in Queensland’s Taroom Trough, confirming reservoir conditions and increasing planned stimulation stages from 11 to 12. Stimulation operations are set to start imminently, aiming to prove commercial gas and condensate flow.

Microba Life Sciences secures $5 million in a placement led by Sonic Healthcare to fund its push towards cashflow break-even by 2027, backed by strong diagnostic sales and AI-driven efficiencies.

Echo IQ has partnered with Mayo Clinic to assess its AI platform's ability to predict heart failure risk in patients undergoing cancer therapy, targeting the growing cardio-oncology sector.

Neometals has completed a second phase of metallurgical testing at its Ironclad gold deposit, delivering gold recoveries that surpass previous assumptions and support near-term project development.

Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.

Imricor Medical Systems has submitted the third of four Premarket Approval modules to the FDA, marking a key step towards US approval of its MR-guided cardiac ablation devices.

Resonance Health is progressing its MRI Liver Fibrosis device through late-stage clinical validation, targeting FDA biomarker qualification, while maintaining a profitable SaaMD platform and forecasting $16 million revenue for FY26.

Elixir Energy has kicked off the stimulation and testing phase at its Lorelle-3H appraisal well, aiming to validate commercial gas and condensate flow rates from Queensland’s Taroom Trough basin-centred gas play.